The Weekly Recap 5/2/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

 In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $35M in new funding, receive FDA 510(k) clearance, expand product lines, and much more on the road to LSI Asia ’25 in Singapore (June 10–13).

Annaida Technologies

Closed an oversubscribed Pre-Series A round to advance its micro-magnetic resonance spectroscopy (micro-MRS) platform for non-invasive embryo analysis. Annaida Technologies will use the funding to accelerate product development and expand market presence in fertility and life sciences, with its Embryospin platform already adopted in top academic labs worldwide.

Azalea Vision

Raised €9M in the first closing of its €15M Series A to advance its intelligent ocular health platform and support a first-in-human pilot clinical trial. Azalea Vision also appointed eyecare industry leader Robert J. Dempsey as Chairman of the Board to guide strategic growth in the United States and Europe.

Bimini Health Tech

Expanded its Essence ADM™ line with the industry’s largest human acellular dermal matrix sheets and added new thickness options to enhance surgical customization. The updated portfolio reflects Bimini Health Tech’s commitment to surgeon-driven innovation and personalized solutions for soft tissue support.

CorWave

Completed six-month in vivo studies of its implantable LVAD, demonstrating reliable pump performance, thromboresistance, and zero device failures — marking the final stage of preclinical development. CorWave is now preparing for its first-in-human clinical trial to bring its self-adaptive, smart heart pump to patients with heart failure.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-5225-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more